WeChat Share

Details

Boston BioForum 2015

Shaping the Biomedical Industry through Collaborative Innovation


Presented by

Chinese-American BioMedical Association (CABA)

Admission

CABA members: FREE; Non-members: $30. On-site membership registration available ($30 annual membership fee due). Dinner social reception: $55. 

Driving Direction & Parking

Please enter the hotel parking garage from Storrow Drive. Parking is complimentary (tickets will be validated at registration).

Symposium Organizing Committee Chair

Eric Shi

Co-Chairs

Yin Chen, Bo Ying and Susan Qu

 

For information about CABA and upcoming events, please check CABA Web site: www.cabaweb.org.

Speakers

Feng Zhang
MIT, Professor
Feng Zhang is the Keck Career Development Assistant Professor of Neuroscience and Biological Engineering at MIT, a New York Stem Cell Foundation-Robertson Investigator and a Core Member of the Broad Institute of MIT and Harvard. As a graduate student at Stanford University, Zhang worked with advisor Karl Deisseroth to invent a set of technologies for dissecting the functional organization of brain circuits. His lab works on developing and applying disruptive technologies including optogenetics and genome engineering (TALENs and CRISPR) to understand nervous system function and disease. Zhang’s long-term goal is to develop novel therapeutic strategies for disease treatment. He obtained a bachelor’s degree from Harvard University and a PhD in chemistry and bioengineering from Stanford University. Before joining the MIT faculty he was a junior fellow of the Harvard University Society of Fellows. He is a recipient of the Waterman Award from the National Science Foundation, the Perl/UNC Prize in Neuroscience, the NIH Director’s Pioneer award, and awards from the Searle Scholars Program, McKnight, Keck, Vallee, and Damon Runyon foundations.
Hui Cai
Wuxi, VP
Prior to WuXi, Dr. Cai spent 10 years at Johnson & Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmune diseases. She is a co-author and co-inventor to over 40 scientific publications and issued or pending patents. Dr. Cai is a Councilor of the American Chemical Society (ACS) and a member of ACS national committee on Chemistry and Public Affairs. She is also a member of the Advisory Council of UCSD IRPS 21th Century China Program, and a member of BayHelix. In her past capacity, she served as a Commissioner at the City of San Diego Science and Technology Commission, Chair of SABPA, and President of SDCA. Dr. Cai received her BS and MS in Chemistry from Peking University, PhD from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a DLA Piper – Athena Scholar.
Katherine J. Turner
Scholar Rock, CSO, SVP
Dr. Turner is an accomplished biotechnology executive and entrepreneur. She is currently Senior Vice President, Research at Scholar Rock, Inc., which is focused on discovering and developing a new class of biologic therapies, "niche modulators," that selectively target dysregulated growth factors in the disease microenvironment. Prior to Scholar Rock, she has served as Vice President at such pioneering companies as Genetics Institute (Protein Discovery), Wyeth (Immunology), and Biogen Idec (Validation Biology). In addition, Dr. Turner has played key scientific leadership roles in start-up companies including Attogen, Inc. Her extensive research and managerial experience encompasses more than 30 years of involvement with all aspects of therapeutic biologics discovery through early clinical development. Her areas of therapeutic expertise include immunology, oncology, hematopoiesis, neurobiology and tissue repair and fibrosis. Dr. Turner has been responsible for the advancement of several therapeutic monoclonal antibodies and played important roles in the development of Neumega®, GM-CSF, PSGL-Ig and IL-13 antagonist. Dr. Turner received her PhD in Biochemistry from Virginia Tech, and pursued post-doctoral training at the Courtauld Institute for Biochemistry (London University) and Brandeis University.
Seng Cheng
Genzyme, a Sanofi Company, Head of Research and Early Development
Seng Cheng is Head of Research and Early Development of the Rare Diseases Division at Genzyme, a Sanofi Company. He received his BSc and PhD degrees in Biochemistry from the University of London, UK and trained as a postdoctoral fellow at the National Institute for Medical Research in London in the field of tumor biology. He worked as a Staff Scientist at Integrated Genetics Inc., and later joined Genzyme Corporation to work on several discovery projects including the structure and function of the cystic fibrosis transmembrane conductance regulator. As Group Vice President of Genetic Diseases Science at Genzyme, he also managed the development of novel gene delivery systems as well as translational research in genetic diseases, a number of which transitioned to clinical testing. Dr Cheng’s current areas of focus include inherited metabolic, muscle, lung and neurodegenerative diseases. He has co-authored 249 research articles and reviews, and is a named co-inventor on 57 issued patents in the area of biotechnology. In his current position, he is responsible for directing the translational research and early clinical development activities in rare genetic diseases.
Craig Wegner
Boston Emerging Innovations Unit, Scientific Partnering & Alliances, AstraZeneca IMED R&D, Exec. Dir. & Head
Dr. Wegner is a passionate translational scientist and strategic leader with over 25 years of academic and biopharmaceutical research experience. He has published peer-review manuscripts, review articles and led small initiative through to large department teams across a number of disease areas and disciplines. Presently, Craig champions an internal Ideation Team, manages AZ’s partnership with the NIH/NCATS and Taiwan NRPB, and leads AstraZeneca’s expanding Open Innovation efforts of partnering internal assets (e.g., compounds) and knowhow with the disease insight and expertise of academic physician- and basic-scientists to collaboratively advance pioneering research and therapies for the benefit of patients.
Peter Reinhart
University of Massachusetts, Amherst, Director, Institute of Applied Life Sciences
http://www.umass.edu/ials/
Zhong Zhong, Ph.D.
Vertex, Vice President of External Research and Innovation of Vertex
Dr. Zhong majored in Genetic Engineering for his undergraduate studies at Fudan University. He earned his PhD at The Rockefeller University with Prof James Darnell Jr. and discovered Stat3 and Stat4 and their roles in cytokine signaling. He also trained with Prof Richard Axel at Columbia University as a Howard Hughes Postdoctoral Fellow of the Life Sciences Research Foundation. Prior to Vertex, Dr. Zhong worked at R.W. Johnson Pharmaceutical Research Institute, Cell & Molecular Technologies Inc, Invitrogen Corp and GlaxoSmithKline. Throughout his industry career, he has built innovative technology platforms, launched new therapeutic area research and most recently, led an integrated discovery and development pipeline from target discovery to POC clinical studies.
Jim Li
Sundia MediTech Co., Ltd. , CEO
Dr. Jim Li is Chief Executive Officer of Sundia MediTech Co., Ltd. Prior to his current role, Dr. Li was Chief Technology Officer and led the Company’s Process & Development and Analytical Research & Development departments, overseeing business development and daily operations including API manufacturing and CMC coordination. Before joining Sundia, Dr. Li spent 18 years working in a variety of positions at a global CRO as well as leading pharmaceutical companies and research institutions, including Wuxi, Wyeth and Cognis. During Dr. Li’s 10-year tenure with Wyeth, he participated in and led numerous drug discovery research programs, including successfully delivering development track compounds for treatment of various diseases such as COPD and Asthma. Dr. Li received a B.S. in Chemistry from Wuhan University, a M.S. in Polymer Science from the Institute of Chemistry, Chinese Academy of Science and a Ph.D. in Organic Chemistry from the University of Central Lancashire, and completed his postdoctoral fellowship at the University of Chicago. To date, Dr. Li has 57 publications and patents.

Panel Discussion: Career Development

A panel discussion on entrepreneurship and career development will be held in the aftenoon. Invited panelists include entrepreneurs, CEOs and career coaching experts.

 


Dr. Wang founded Shenzhen TargetRx, Inc., in Aug 2014 and is now the  President/CEO. He  was the Associate Director of Chemistry at ARIAD  Pharmaceuticals, Inc., until April 2013.  Yihan Wang received his B.Sc. in  chemistry from University of Science and Technology of  China, and Ph.D.  in chemistry from New York University. Yihan’s research has focused    primarily on medicinal chemistry in the area of signal transduction drug  discovery,  integrating structure-based drug design, combinatorial  chemistry, and both biological and  pharmacological assays to identify  small-molecule clinical candidates. His career at ARIAD  includes innovative research in therapeutic areas involving bone diseases and cancer, and has  been a key contributor to the discovery of several clinical drugs, including Ponatinib (iClusigTM) (approved by the FDA for resistant CML in Dec 2012), Brigatinib (AP26113, Phase II for NSCLC), Ridoforolimus (Phase III for Sarcoma and multiple Phase II), and several pre-clinical compounds. Yihan is the primary author of approximately 90 peer-reviewed publications, patents, and invited meeting talks. Yihan is the editor of “Chemical Biology and Drug Design” and a reviewer for many professional journals. 

Yihan is one of the co-founders of Chinese-American BioMedical Association (CABA) and currently on the Board of Directors.    


Yueming Wang, BA, MBA, IPEM, is Chairman and General Manager of  Zhongyuan Pharmaceutical Co., Ltd, in Beijing, a new affiliation of Zhongyuan  Union Stem & Cell Engineering Corporate Co., Ltd, in Tianjin, a listed company in  China. Yueming joined the Zhongyuan Union in early 2014 and has been serving  as the Director of Human Resources and Chairman of Alliancells Biosciences., Ltd,  another affiliate of the Zhongyuan Union.

 In January 2015, Yueming completed his master program courses in International    Pharmaceutical Engineering Management (IPEM) at Peking University. He obtained his MBA from Maryville University St. Louis, U.S., and returned home in May 1998. He worked for Beijing Tide Pharmaceutical Co., Ltd, as Deputy General Manager in charge of human resources and pharmaceutical/R&D facility construction projects between October 1999 and January 2014.



Lauren Celano is the Co-founder and CEO of Propel Careers, a life science search  and career development firm focused on connecting talented individuals with  entrepreneurial  innovative life sciences companies.  Lauren is very passionate  about working with individuals with strong scientific backgrounds to find exciting  growth opportunities in the life sciences industry. Before Propel, she spent about 10  years in the life sciences industry working with companies to advance drug  molecules through SNBL USA, Aptuit, Quintiles, and Absorption Systems. She has  a B.S. in Biochemistry and Molecular Biology from Gettysburg College and an MBA  with a focus in the health sector and entrepreneurship from Boston University.    Lauren is on the Board of MassBioEd, the Advisory Board of the Boston University School of Public Health Pharmaceuticals Program, and the Advisory board for Endicott College Boston. She also serves on the programming committee of the Capital Network.


Registration

Type Sales End Price Quantity

Registration only

2015-05-09 21:00 $30

Registration+annual membership

2015-05-09 21:00 $30

Dinner

2015-05-07 09:00 $55

Registration for active CABA members (Membership will be checked onsite)

2015-05-09 21:00 $0

Registration for students

2015-05-09 21:00 $15

Registration + student annual membership

2015-05-09 21:00 $15

About CABA

Chinese-American BioMedical Association (CABA) is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development. As the majority of its members are scientists with Chinese heritage, CABA will operate in two important areas. One is to serve as a platform for its members to develop and advance their careers in the US pharmaceutical and biomedical industry, the other is to serve as a bridge to connect members including corporate members with the scientific and business resources in China thus facilitating collaboration between the pharmaceutical and biomedical industries across continents. To fulfill these goals, we will organize scientific and business symposia, conferences, workshops, in US and China, as well as social events to promote networking and communication among members. We will bring together members, scientists, professionals, government officials and business leaders across the continents under a collaborative environment and achieve their best potentials. 

CABA is a volunteer-based society. We rely on members to contribute their time and efforts to build the organization. We rely on corporate members and sponsors to raise fund to support the above activities. We value integrity, honesty, professionalism, community service, scientific excellence, responsibility and accountability. We invite you to explore our organization, and we are confident you will share our values and are interested in becoming a member, devoting your time or efforts, or sponsoring CABA activities. In summary, CABA is built by its members and serves for its members.


www.cabaweb.org

Date Time

2015-05-09 09:00 - Start

2015-05-09 21:00 - End

Ended
Address
  • 400 Soldiers Field Road , BOSTON  MA  02134

Contact Us

Your Name: *
Your Email: *
Cell phone:
Subject: *
Message: *